Search results
Showing 1 to 15 of 15 results for bronchiectasis
Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing (NG117)
This guideline sets out an antimicrobial prescribing strategy for managing and preventing acute exacerbations of bronchiectasis (non-cystic fibrosis). It aims to optimise antibiotic use and reduce antibiotic resistance.
Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over [ID6448]
In development Reference number: GID-TA11564 Expected publication date: 08 July 2026
Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115)
This guideline covers diagnosing and managing chronic obstructive pulmonary disease or COPD (which includes emphysema and chronic bronchitis) in people aged 16 and older. It aims to help people with COPD to receive a diagnosis earlier so that they can benefit from treatments to reduce symptoms, improve quality of life and keep them healthy for longer.
This indicator covers the percentage of patients with moderate or severe frailty and/or multimorbidity who have received a medication review in the last 12 months which is structured, has considered the use of a recognised tool and taken place as a shared discussion. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM186
Evidence-based recommendations on bronchial thermoplasty for severe asthma in adults. This involves applying heat to the inside walls of the airways.
View recommendations for HTG494Show all sections
Idiopathic pulmonary fibrosis in adults: diagnosis and management (CG163)
This guideline covers diagnosing and managing idiopathic pulmonary fibrosis in people aged 18 and over. It aims to improve the quality of life for people with idiopathic pulmonary fibrosis by helping healthcare professionals to diagnose the condition and provide effective symptom management.
This guideline sets out an antimicrobial prescribing strategy for acute cough associated with an upper respiratory tract infection or acute bronchitis in adults, young people and children. It aims to limit antibiotic use and reduce antibiotic resistance.
This guideline covers diagnosing and managing cystic fibrosis. It specifies how to monitor the condition and manage the symptoms to improve quality of life. There are also detailed recommendations on treating the most common infections in people with cystic fibrosis.
Evidence-based recommendations on leniolisib (Joenja) for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over.
Lung texture analysis for measuring interstitial lung diseases (MIB272)
NICE has developed a medtech innovation briefing (MIB) on lung texture analysis for measuring interstitial lung diseases .
This quality standard covers the initial assessment and management of suspected acute respiratory infection in over 16s, including acute respiratory infection virtual wards.
View quality statements for QS210Show all sections
Sections for QS210
- Quality statements
- Quality statement 1: Documented initial assessment
- Quality statement 2: Prescribing antimicrobials
- Quality statement 3: Antibiotic duration
- Quality statement 4: Information about acute respiratory infection virtual wards
- Quality statement 5: Multidisciplinary team
- Quality statement 6: Support to self-manage on a virtual ward
- Quality statement 7: Virtual ward discharge summaries
Non-cystic fibrosis bronchiectasis: colistimethate sodium (ESUOM25)
This evidence summary has been updated and replaced by NICE guideline NG117.
Non-cystic fibrosis bronchiectasis: inhaled tobramycin (ES12)
This evidence summary has been updated and replaced by NICE guideline NG117.
Non-cystic fibrosis bronchiectasis: long-term azithromycin (ESUOM38)
This evidence summary has been updated and replaced by NICE guideline NG117.
This guideline covers how to increase uptake of the free flu vaccination among people who are eligible. It describes ways to increase awareness and how to use all opportunities in primary and secondary care to identify people who should be encouraged to have the vaccination.